Case of Basal Cell Prostate Cancer and Recurrence With Prostatic Adenocarcinoma in a United States Military Veteran Exposed to Agent Orange Authors: German Santiago Herrera Alzate, Piroz Bahar, Daniel S. Levin, Andrew Wood, Arvin K. George, Paul J. Chuba Published: 2026 ABSTRACT ABSTRACTProstate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men. Acinar adenocarcinoma accounts for 90% of primary prostatic cancers. Carcinoma of the basal cells of the prostate is extremely rare, making up less than 1% of prostate cancer diagnoses. As opposed to adenocarcinoma, basal cell‐type carcinoma of the prostate (BCCP) does not usually secrete PSA and most commonly presents with symptoms of typical BPH. Due to its nonspecific symptoms and absence of PSA secretion, it is often diagnosed at the locally advanced stage. In part due to its rarity, there are no standardized treatment protocols. Agent Orange (AO) is a pesticide utilized by the US Military during the Vietnam War, which was contaminated with polychlorinated dibenzo‐dioxins (PCDDs). These compounds have been linked to the development of various malignancies, including prostate cancer, although a direct causal relationship remains unproven. We present the case of a US Vietnam Veteran with Agent Orange exposure who was diagnosed with multiple distinct types of prostate cancer, including BCCP. He was initially found to have BCCP on pathological evaluation of prostate tissue from a prostatic resection for BPH. He was treated with definitive radiotherapy. He subsequently developed a recurrence of prostate cancer, but on this occasion, he was found to have localized prostatic adenocarcinoma and was treated with salvage High Intensity‐Focused Ultrasound (S‐HIFU). He remained without recurrence to the time of the writing of this report, 60 months after undergoing S‐HIFU. Upon review of the literature, there is a lack of data regarding the environmental exposures of patients who develop BCCP, as well as a lack of documentation of rare subtypes of prostate cancers that have been identified in AO‐exposed Veterans. Further studies on this subject would be beneficial, as there are millions of US veterans alive who had exposure to PCDDs during the Vietnam War and the more recent Global War on Terror. Introduction In 2025, there are estimated to be 1,053,250 new cases of cancer diagnosed in men in the United States, with prostate cancer making up 30% of these new cases [1]. Though there has been a recent decrease in cancer mortality overall, prostate cancer maintains a high mortality burden as the second leading cause of cancer death in men [2]. 90% of prostate cancers are acinar epithelial in origin, originating from secretory acini, and present as adenocarcinoma [3, 4]. Non‐acinar variants make up less than 2%. Within this category, basal cell‐type epithelial carcinoma of the prostate (BCCP) is an extraordinarily rare subtype, making up less than 0.01% of prostate cancers [5]. As opposed to adenocarcinoma, BCCP does not secrete PSA, making it more difficult to identify on routine screening [6]. Due to the rarity of this subtype, a standard treatment modality has not been established. However, it has recently been distinguished as a potentially aggressive tumor, commonly presenting with locally advanced disease, often incidentally identified during prostate resections for Benign Prostatic Hyperplasia (BPH) [7, 8]. During the Vietnam War, the United States utilized phenoxy‐herbicides, colloquially known as Agent Orange (AO), as part of a campaign to defoliate inland hardwood and coastal mangrove forests and clear perimeters for military bases. As a byproduct of manufacture, these herbicides were contaminated with 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin (TCDD), a highly toxic and oncogenic chemical. Agent Orange was sprayed from C‐130 aircraft, trucks, and spray units mounted on soldiers' backs [9, 10]. By the end of the war, nearly 10% of South Vietnam had been sprayed with approximately 19 million gallons of Agent Orange. Polychlorinated dioxins, and specifically 2,3,7,8‐TCDDD have subsequently been deemed a probable human carcinogen by the EPA [11]. Studies on military veterans exposed to AO have found an increased incidence of urological cancers, including prostate cancer. Furthermore, the exposed veterans were younger at the onset of disease, had a two‐fold increase in the proportion of high‐grade disease, and were more likely to have metastasis at presentation [10]. We herein present a case of a United States Military Veteran with AO exposure who was incidentally found to have BCCP on a simple prostatectomy for presumed BPH and underwent definitive radiation therapy. He subsequently had a recurrence of prostate cancer, but on the second occasion was found to have conventional prostatic adenocarcinoma and was treated with salvage High‐intensity focused ultrasound (S‐HIFU) therapy. Case History/Examination A 62‐year‐old male Military Veteran with a past medical history of former smoking, AO exposure, and previous employment in the sheet metal industry presented with complaint of obstructive voiding symptoms. His PSA was 0.76, and he had a markedly enlarged prostate with a volume of 462 CC. He underwent an open simple partial suprapubic prostatectomy for presumed obstructive BPH. The pathology demonstrated Basal Cell Carcinoma of the prostate. A post‐operative CT demonstrated suggestion of tumor invasion into the seminal vesicles and left and right sides of the bladder wall, without evidence of adenopathy (Figure 1). He was staged as T3NX. For definitive management, he underwent external beam radiation via Intensity Modulated Radiation Therapy (IMRT). He received a primary dose of 4500 cGy in 25 fractions targeting the prostate and seminal vesicles, followed by an IMRT prostate boost of 3240 cGy in 18 fractions, bringing the cumulative dose to 7740 cGy. After treatment, his PSA nadired at 0.04 at 24 months and slowly increased. However, between 72 and 96 months, his PSA significantly increased from 0.6 to 6.1. CT urogram obtained 1 month after simple suprapubic prostatectomy, demonstrating obliteration of the seminal vesicle angles and marked circumferential bladder wall thickening, raising concern for tumor invasion. Differential Diagnosis, Investigations, and Treatment Due to the elevation in PSA, a Prostate MRI was performed, which demonstrated a 39 cc prostate and a mass in the right posterior peripheral zone, 6 mm in size, PIRADS score of 4 (Figure 2). PSMA PETCT showed intense uptake in the right posterior peripheral zone with SUV max of 10.1 (Figure 3), consistent with prostate cancer. There was no evidence of nodal or distant metastasis. Biopsy of this mass was consistent with prostatic adenocarcinoma, Gleason score 4 + 4 = 8, grade group 4. There was no evidence of recurrent BCCP. Given the localized nature of the recurrence, a S‐HIFU hemi‐gland ablation of the right prostate was performed. (A) Preoperative T2 MRI Demonstrating a 6 mm hypointense focus within the right posterior peripheral zone, suspicious for prostate cancer. PI‐RADS 4. (B) High B‐value (1500) DWI MRI showing a correlating area of marked hyperintensity in the right posterior peripheral zone of the prostate. Pre‐operative PSMA PETCT demonstrating a focal area of increased radiotracer uptake with an SUV max of 10.1 in the right posterior peripheral zone of the prostate. Conclusion and Results (Outcome and Follow‐Up) The preoperative AUA Symptom Index Score (AUASS) was 4/35 (mild), and the Sexual Health Inventory for Men (SHIM) score was 1/25, indicating severe erectile dysfunction (ED). An MRI performed 3 months after the procedure showed a complete ablation response (Figure 4). A subsequent biopsy 7 months after the procedure and PSMA PET 12 months after the procedure confirmed no residual viable tumor (Figure 5). At 34 months after HIFU, his AUASS score was 6/35, and his severe ED persisted, with SHIM remaining at 1/25. The patient remained in remission from prostate cancer to the writing of this report, 60 months after undergoing S‐HIFU. (A) Post‐operative T2 MRI demonstrating complete resolution of abnormal focus within the right posterior peripheral zone. (B) Diffusion weighted MRI without evidence of abnormal signal intensity or enhancement in the treatment zone. A 3‐month post‐operative PSMA PETCT demonstrating resolution of area of increased 68Ga‐PSMA increased uptake in the right posterior peripheral zone. Replaced by an area of photopenia consistent with successful ablation. Discussion Basal cell carcinoma of the prostate is an extremely rare form of prostate cancer, with approximately 100 cases reported in the literature in comparison to hundreds of thousands of cases of prostatic adenocarcinoma diagnosed yearly in the United States [1, 8]. This has created difficulty in defining its characteristics and morbidity. Microscopically, these cancers closely resemble adenoid cystic carcinomas of the salivary glands [12]. The cells may be arranged in patterns, including adenoid cystic, small solid nests with peripheral palisading cells, or in a basal cell hyperplasia type pattern with large solid nests. Ultimately, BCCP may be differentiated from basal cell hyperplasia by the expression of BCL‐2 and Ki‐67 [12]. As was the case for this patient, the peak incidence for BCCP is 60–75 years of age; however, there have been reports of cases in younger adults [8]. Since BCCP arises from basal epithelial cells rather than glandular acinar cells of the prostate, it does not express PSA. Therefore, PSA is not feasible to be utilized to screen or evaluate for disease recurrence. In this patient's case, the PSA of 0.76 was significantly lower than what would be anticipated for a prostate size of 462 cc, attributable to BPH. This discordance is possibly the only indication that prostate enlargement of this type is not due to BPH, but instead due to a non‐PSA‐secreting malignancy such as BCCP [13]. No preoperative imaging has been shown to accurately distinguish BCCP from other prostate malignancies or BPH. Consequently, patients are typically diagnosed through histopathological analysis following prostate resections [8]. Since the primary presenting symptoms are obstructive urinary symptoms, without PSA elevation, most patients with BCCP are treated for BPH symptoms, leading to delays in diagnosis and treatment. This delay has likely contributed to the diagnosis of most cases at the locally advanced stage, with encroachment onto adjacent pelvic structures [8]. BCCP also has the capacity to display metastatic behavior, mainly to the lung and liver [6, 8]. Given the rarity of the disease, there are no standardized treatments for BCCP. Prior treatment protocols have been extrapolated from the treatment of adenoid cystic carcinomas of the head and neck, due to the histopathological similarity. The spectrum of treatment modalities has included radical prostatectomy, neoadjuvant chemotherapy and radical prostatectomy, TURP plus radiation therapy, and TURP plus chemotherapy. Recently, a patient with recurrent BCCP with metastases to the liver following radical prostatectomy was found to have a FGFR2‐TACC2 fusion transcript mutation on genetic testing of the tumor [6]. He was treated with the FGFR inhibitor Pemigatinib with good response [6]. In a literature review of 75 patients treated with a mixture of radical prostatectomy and TURP, 28 (37%) developed disease progression and eventually died from the disease [14]. The surgical options for patients with radiation‐recurrent prostate cancer include salvage radical prostatectomy (S‐RP), Salvage Cryotherapy, and S‐HIFU. In comparison to S‐RP, S‐HIFU is associated with significantly improved functional outcomes, with 22% of S‐HIFU patients requiring pads at 12 months versus 56% of patients undergoing S‐RP. The improvement in functional outcomes does not compromise the efficacy of treatment, with S‐HIFU vs. S‐RP patients having no statistically significant decrease in overall survival or metastasis‐free survival over 5 years. Furthermore, S‐HIFU has been associated with a decreased number of Clavien ≥ 3 surgical complications (9% vs. 16%, p = 0.027) in comparison to S‐RP [15, 16]. In this patient, the AUASS remained stable (6/35) at 34 months post‐S‐HIFU, and his sexual function remained low (1/25). The future of Salvage Focal therapy (SFT) is a developing space; future practice may include the addition of systemic therapies such as androgen deprivation therapy (ADT) to S‐HIFU to maximize functional outcomes and minimize recurrence rates [17]. On review of the limited BCCP literature, there was no mention of patient environmental exposures. Multiple studies have identified an association between AO exposure and the development of high‐grade prostate malignancies [10, 18], primarily in the context of conventional adenocarcinoma [10, 18, 19]. To our knowledge, there is a lack of evidence specifically linking AO exposure to rare prostate cancer subtypes such as BCCP. The average age of Vietnam veterans today is around 75 years old, an age with an elevated risk for prostate malignancies. Further work is needed to elucidate whether there is a relationship between AO exposure and the development of rare variants of prostate cancer. If such a relationship is established, veterans with AO exposure could benefit from increased workup for substantial BPH enlargement, particularly in the setting of discordant PSA values. Furthermore, there are more than 3 million US service members who served in the Global War on Terror and were exposed to polychlorinated dioxins similar to AO [20]. The largest cohort of these veterans is between the ages of 35–54 and will soon arrive at an age where the chemical exposures they suffered may predispose them to the development of prostate cancer. BCCP, an extremely rare form of prostate cancer, commonly presents with obstructive urinary symptoms and a normal PSA and can easily be mistaken for BPH. For this reason, BCCP is commonly diagnosed at the locally advanced stage upon histopathological evaluation of prostate resection specimens. BCCP has considerable potential for local infiltration and metastasis [8, 14]. The environmental exposure of patients presenting with this rare malignancy is not reported in the current literature. There are millions of aging Vietnam and GWOT veterans who had exposures to polychlorinated dioxins, which have been associated with a variety of cancers [20]. Given the association between environmental exposures and urological cancers, it would be valuable to establish the exposures of patients presenting with BCCP and other rare forms of urological malignancies to aid in the development of standardized screening practices, particularly in high‐risk groups such as US military veterans [18, 21]. S‐HIFU, a modern minimally invasive technique, is an effective management strategy that can be utilized to treat patients with prostate cancer recurrence while improving functional outcomes. This can be useful in maintaining quality of life in toxin‐exposed veterans who may be predisposed to developing various forms of prostate cancer and may necessitate multiple interventions. Author Contributions German Santiago Herrera Alzate: investigation, resources, writing – original draft. Piroz Bahar: conceptualization, resources, writing – review and editing. Daniel S. Levin: investigation, writing – review and editing. Andrew Wood: conceptualization, supervision, writing – review and editing. Arvin K. George: resources, writing – review and editing. Paul J. Chuba: investigation, resources. Funding The authors have nothing to report. Ethics Statement Institutional Review Board (IRB) approval was not required for single‐patient case reports, in accordance with institutional policy. Patient anonymity has been maintained, and written informed consent was obtained for the publication of all relevant clinical information and images. Consent Written informed consent was obtained from the patient for the publication of this case report, including the use of clinical information and radiographic images. The patient was made aware that identifying information would be kept confidential and that all efforts would be made to maintain anonymity. Conflicts of Interest The authors declare no conflicts of interest.